New Gene Therapy Successfully Reverses Congenital Deafness
New Gene Therapy Successfully Reverses Congenital Deafness
A groundbreaking medical milestone has arrived: gene therapy is now successfully reversing congenital deafness in patients with OTOF-related hearing loss.
This condition prevents the body from producing otoferlin, a protein necessary for transmitting sound to the brain.
Researchers use a harmless virus to deliver a functional OTOF gene directly into the inner ear, allowing cells to produce the missing protein.
Unlike cochlear implants that use electronics, this therapy repairs the biological machinery itself.
The trials, including the CHORD study, show the procedure is safe and effective even in older children and adults.
This transition from merely managing symptoms to treating the root cause marks a historic shift in medicine.
While currently focused on OTOF mutations, this success serves as a blueprint for curing other forms of genetic hearing loss, offering hope that many previously permanent conditions may soon be treatable.
